Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T88126 Target Info
Target Name Bacterial Nicotinate-nucleotide adenylyltransferase (Bact nadD)
Synonyms nadD of Escherichia coli (strain K12); Nicotinate mononucleotide adenylyltransferase of Escherichia coli (strain K12); NaMN adenylyltransferase of Escherichia coli (strain K12); Deamido-NAD(+)Nicotinate-nucleotide adenylyltransferase pyrophosphorylase of Escherichia coli (strain K12); Deamido-NAD(+) pyrophosphorylase of Escherichia coli (strain K12); Deamido-NAD(+) diphosphorylase of Escherichia coli (strain K12)
Target Type Patented-recorded Target
Gene Name Bact nadD
Biochemical Class Kinase
UniProt ID
NADD_ECOLI
Patent(s) and the Corresponding Patented Drug(s)  Top
United States Patent and Trademark Office (USPTO)
Patent ID US8785499
Title Targeting NAD biosynthesis in bacterial pathogens
Abstract The emergence of multidrug-resistant pathogens necessitates the search for new antibiotics acting on previously unexplored targets. Nicotinate mononucleotide adenylyltransferase of the NadD family, an essential enzyme of NAD biosynthesis in most bacteria, was selected as a target for structure-based inhibitor development. To this end, the inventors have identified small molecule compounds that inhibit bacterial target enzymes by interacting with a novel inhibitory binding site on the enzyme while having no effect on functionally equivalent human enzymes.
Applicant(s) University of Maryland, Baltimore; The Board of Regents of the University of Texas System; Sanford-Burnham Medical Research Institute
Representative Drug(s) D0UF5V Drug Info IC50 = 15000 nM Click to Show More [1]
2 D0ND9W Drug Info IC50 = 51000 nM [1]
3 D0A0BS Drug Info IC50 = 65000 nM [1]
Patent ID US8785499
Title Targeting NAD biosynthesis in bacterial pathogens
Abstract The emergence of multidrug-resistant pathogens necessitates the search for new antibiotics acting on previously unexplored targets. Nicotinate mononucleotide adenylyltransferase of the NadD family, an essential enzyme of NAD biosynthesis in most bacteria, was selected as a target for structure-based inhibitor development. To this end, the inventors have identified small molecule compounds that inhibit bacterial target enzymes by interacting with a novel inhibitory binding site on the enzyme while having no effect on functionally equivalent human enzymes.
Applicant(s) University of Maryland, Baltimore; The Board of Regents of the University of Texas System; Sanford-Burnham Medical Research Institute
Representative Drug(s) D0UF5V Drug Info IC50 = 15000 nM Click to Show More [1]
2 D0ND9W Drug Info IC50 = 51000 nM [1]
3 D0A0BS Drug Info IC50 = 65000 nM [1]
Patent ID US8785499
Title Targeting NAD biosynthesis in bacterial pathogens
Abstract The emergence of multidrug-resistant pathogens necessitates the search for new antibiotics acting on previously unexplored targets. Nicotinate mononucleotide adenylyltransferase of the NadD family, an essential enzyme of NAD biosynthesis in most bacteria, was selected as a target for structure-based inhibitor development. To this end, the inventors have identified small molecule compounds that inhibit bacterial target enzymes by interacting with a novel inhibitory binding site on the enzyme while having no effect on functionally equivalent human enzymes.
Applicant(s) University of Maryland, Baltimore; The Board of Regents of the University of Texas System; Sanford-Burnham Medical Research Institute
Representative Drug(s) D0UF5V Drug Info IC50 = 15000 nM Click to Show More [1]
2 D0ND9W Drug Info IC50 = 51000 nM [1]
3 D0A0BS Drug Info IC50 = 65000 nM [1]
References  Top
REF 1 Targeting NAD biosynthesis in bacterial pathogens. US8785499.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.